US · Healthcare · Diagnostics & Research
EPS came in at 3.12 against a street estimate of 2.81 — a beat of 11.0%.
Analysts rate Quest Diagnostics Incorporated a buy (9 buy, 9 hold, 0 sell out of 18) with an average price target of $245.87.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.31% |
| Vanguard Capital Management, LLC | 6.47% |
| T. Rowe Price Associates, Inc. | 5.71% |
| Vanguard Portfolio Management, LLC | 5.51% |
| State Street Corp | 4.88% |
| Boston Partners Global Investors, Inc | 3.64% |
| JPMorgan Chase & Co | 3.48% |
| Geode Capital Management, LLC | 2.80% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-23 |
| Results announced · Q3 2026 | 2026-07-23 |
| Shareholder vote results · Q2 2026 | 2026-05-21 |
| Material agreement · Q2 2026 | 2026-05-08 |
| Company announcement · Q2 2026 | 2026-05-01 |
| Quarterly report · Q1 2026 | 2026-04-22 |
| Proxy statement · Q2 2026 | 2026-04-06 |
| Annual report FY2025 | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes $1B stock repurchase and raises quarterly dividend 7.5% Quest Diagnostics announced its fourth quarter and full-year 2025 financial results on February 10, 2026. Beyond reporting earnings, the company made two shareholder-friendly announcements t | 2026-02-10 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Quest Diagnostics Incorporated — free to start.
Google PlayApp StoreData updated 2026-08-05.